PM
MIRM icon

Prosight Management’s Mirum Pharmaceuticals MIRM Stock Holding History

Prosight Management’s Portfolio MIRM Stock Details MIRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-200,000
Closed -$10.2M – 47
2025
Q2 		$10.2M Sell
200,000
-143,326
-42% -$6.38M 2.48% 13
2025
Q1 		$15.5M Sell
343,326
-107,801
-24% -$5.08M 5.08% 6
2024
Q4 		$18.7M Sell
451,127
-14,698
-3% -$612K 5.16% 7
2024
Q3 		$18.2M Buy
465,825
+151,025
+48% +$6.02M 4.47% 8
2024
Q2 		$10.8M Sell
314,800
-150,200
-32% -$3.94M 3.22% 11
2024
Q1 		$11.7M Buy
465,000
+171,699
+59% +$4.72M 3.25% 11
2023
Q4 		$8.66M Sell
293,301
-60,207
-17% -$1.82M 3.48% 12
2023
Q3 		$11.2M Sell
353,508
-321,492
-48% -$8.8M 3.54% 10
2023
Q2 		$17.5M Buy
675,000
+107,174
+19% +$2.85M 5.11% 6
2023
Q1 		$13.6M Buy
567,826
+259,050
+84% +$5.9M 6.47% 3
2022
Q4 		$6.02M Buy
308,776
+23,776
+8% +$470K 3.28% 10
2022
Q3 		$5.99M Buy
285,000
+123,473
+76% +$2.97M 3.21% 12
2022
Q2 		$3.14M Buy
161,527
+87,597
+118% +$2.07M 2.48% 16
2022
Q1 		$1.63M Buy
+73,930
New +$1.51M 1.05% 23
2021
Q1 		– Sell
-60,250
Closed -$1.05M – 45
2020
Q4 		$1.05M Buy
+60,250
New +$1.18M 0.49% 35

Other funds holding MIRM

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Prosight Management's MIRM Position: Q3 2025 in Review

Prosight Management sold out of Mirum Pharmaceuticals (MIRM) in Q3 2025, closing a stake of 200,000 shares — an estimated $10.2M sold.

Prosight Management first reported a position in MIRM in Q4 2020 and held it in 15 quarters. The position peaked at $18.7M in Q4 2024. 272 funds tracked by Wall St. Rank hold MIRM as of Q3 2025.

  • Prosight Management reported no remaining Mirum Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Prosight Management sold 200,000 Mirum Pharmaceuticals shares in Q3 2025, an estimated $10.2M.
  • Prosight Management first reported a position in Mirum Pharmaceuticals in Q4 2020 and held it in 15 quarters.
  • Prosight Management's Mirum Pharmaceuticals position peaked at $18.7M in Q4 2024.
  • 272 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q3 2025.

Based on Prosight Management's 13F filing for Q3 2025, filed 14 Nov 2025.